Effect of COVID-19 Pandemic on Gynecological Cancer Radiation During Complete Nationwide Lockdown: Observations and Reflections From Tertiary Care Institute in India.
Journal
Advances in radiation oncology
ISSN: 2452-1094
Titre abrégé: Adv Radiat Oncol
Pays: United States
ID NLM: 101677247
Informations de publication
Date de publication:
Historique:
received:
22
11
2020
revised:
29
04
2021
accepted:
07
05
2021
pubmed:
3
6
2021
medline:
3
6
2021
entrez:
2
6
2021
Statut:
ppublish
Résumé
To report real-world compliance to radiation in gynecologic cancers during the complete lockdown phase of COVID-19 pandemic. From March 23, 2020, until June 30, 2020, complete lockdown was imposed in India. During this period there was restructuring of cancer care and radiation oncology department due to operational policies prevalent in the institution, and the care for gynecological cancer was based on the evolving international recommendations. Institutional review board approval was obtained to audit patterns of care during the complete lockdown phase. Descriptive variables were used to report on patient characteristics, compliance, delays, toxicity, and observed deviations in recommended care. During the lockdown period spanning 100 days, treatment of 270 and telephonic follow-up of 1103 patients with gynecological cancer was undertaken. Of 270 new patients, due to travel restrictions, 90 patients were referred to the facilities in vicinity of their residence. Of the remaining 180 patients, 138 were planned for complete treatment at our institution and 42 were referred to our center for brachytherapy. Of 138 patients, only 106 (76%) completed the planned external radiation. Twenty-four (26%) patients completed full course of concurrent chemotherapy, 11 (12%) received chemotherapy dose reduction, and 57 (62%) received no concurrent chemotherapy. Treatment delay of up to 3 weeks was noted in 8.6% patients due to COVID-19 infection. No grade 4 to 5 acute sequelae were observed. No excess adverse effects were observed in high-risk population. Low rate of symptom burden was observed among 1103 patients on telephonic follow-up. With 100 (9.6%) patients reporting symptoms, among these, 54% (54 of 100) had complete resolution of symptoms within 4 weeks of teleconsultation, and 10% had disease progression. Low compliance with planned treatment was observed for radiation and concurrent chemotherapy due to lockdown and fear of contracting COVID-19 and will likely lead to increased risk of cancer-related mortality. Rapid restructuring of care is needed to prevent the same as COVID-19 pandemic further evolves.
Identifiants
pubmed: 34075350
doi: 10.1016/j.adro.2021.100725
pii: S2452-1094(21)00083-X
pmc: PMC8159674
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100725Informations de copyright
© 2021 The Authors.
Références
Oncotarget. 2017 Jul 27;8(49):85203-85213
pubmed: 29156713
N Engl J Med. 2020 May 14;382(20):e61
pubmed: 32343498
J Radiosurg SBRT. 2020;7(2):89-94
pubmed: 33282462
Radiother Oncol. 2020 Aug;149:25-29
pubmed: 32389755
SN Compr Clin Med. 2020 Jul 15;:1-4
pubmed: 32838167
Clin Transl Radiat Oncol. 2018 Jan 11;9:48-60
pubmed: 29594251
Int J Radiat Oncol Biol Phys. 2020 Oct 1;108(2):462-465
pubmed: 32890533
Int J Radiat Oncol Biol Phys. 2020 Oct 1;108(2):411-415
pubmed: 32890523
Radiother Oncol. 2020 Sep;150:40-42
pubmed: 32544604
Rep Pract Oncol Radiother. 2015 Sep-Oct;20(5):328-39
pubmed: 26549990
Int J Gynecol Cancer. 2020 Sep;30(9):1424-1433
pubmed: 32576608
J Clin Oncol. 2018 Jun 1;36(16):1548-1555
pubmed: 29432076
Adv Radiat Oncol. 2020 Apr 18;5(4):525-526
pubmed: 32313846
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Gynecol Oncol. 2020 Aug;158(2):244-253
pubmed: 32563593
Science. 2020 Jun 19;368(6497):1290
pubmed: 32554570
JAMA Otolaryngol Head Neck Surg. 2020 Dec 1;146(12):1102-1108
pubmed: 32880626
Radiother Oncol. 2005 Jan;74(1):31-5
pubmed: 15683666
J Clin Oncol. 2008 Dec 10;26(35):5802-12
pubmed: 19001332
Lancet Oncol. 2020 May;21(5):634-636
pubmed: 32359487
Lancet Oncol. 2020 Apr;21(4):e181
pubmed: 32142621
Am J Clin Oncol. 2020 Jun;43(6):452-455
pubmed: 32304435
J Glob Oncol. 2018 Jul;4:1-9
pubmed: 30085892
Adv Radiat Oncol. 2020 Jun 02;5(4):640-643
pubmed: 32775774
Int J Radiat Oncol Biol Phys. 2020 Oct 1;108(2):356-361
pubmed: 32890512
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
Rep Pract Oncol Radiother. 2020 Sep-Oct;25(5):820-827
pubmed: 32837336
Cancer. 2013 Jan 15;119(2):325-31
pubmed: 22806897
JAMA Oncol. 2018 Apr 1;4(4):506-513
pubmed: 29423520
J Glob Oncol. 2018 Jul;4:1-15
pubmed: 30085891
Indian J Gynecol Oncol. 2020;18(3):101
pubmed: 32974420
Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1275-88
pubmed: 7635767
Indian J Cancer. 2020 Apr-Jun;57(2):123-128
pubmed: 32445314